CVS Health Corporation (CVS)
CVS Health combines a national retail pharmacy chain, the Aetna health-insurance business, and the Caremark pharmacy-benefit manager. This integrated model spans much of the US prescription-drug supply chain.
Health Care stock comparison
| Company fact | CVS | DHR |
|---|---|---|
| Company | CVS Health Corporation | Danaher Corporation |
| Exchange | NYSE | NYSE |
| Headquarters | Woonsocket, Rhode Island | Washington, District of Columbia |
| Founded | 1963 | 1969 |
| SEC industry | Retail-Drug Stores and Proprietary Stores | Industrial Instruments For Measurement, Display, and Control |
| Fiscal year-end | December 31 | December 31 |
| Latest annual filing | 10-K · 2026-02-10 | 10-K · 2026-02-24 |
CVS Health combines a national retail pharmacy chain, the Aetna health-insurance business, and the Caremark pharmacy-benefit manager. This integrated model spans much of the US prescription-drug supply chain.
Danaher is a science and technology conglomerate focused on life sciences, diagnostics, and biotechnology after divesting its industrial businesses. Its recurring consumables and reagents generate steady demand.
The useful starting point is not which ticker has performed better. It is whether the two companies convert the same economic forces into revenue and cash flow in the same way. CVS is classified by the SEC as Retail-Drug Stores and Proprietary Stores, while DHR is classified as Industrial Instruments For Measurement, Display, and Control. The different industry codes are a warning against treating sector membership as proof of identical economics.
Use the distinction below to decide which filing deserves deeper work. It is a research routing rule, not a recommendation or prediction.
Start with primary filings because fiscal calendars and accounting presentation can make superficially similar quarters incomparable.CVS's fiscal year ends December 31, while DHR's ends December 31. Normalize the reporting periods before comparing growth, margins, capital intensity, or guidance.
The current verified House Clerk snapshot contains 0matched transaction rows for CVSand 0 for DHR. These delayed, range-based disclosures can identify a filing to inspect; they do not establish motive, conviction, or a real-time trading signal.
This page does not contain licensed live prices, a valuation model, earnings estimates, portfolio constraints, or a forecast of future returns. SEC classifications can be broad, company descriptions can lag strategic change, and the latest annual filing may predate a material acquisition or divestiture. Read subsequent quarterly and current reports before making a decision.
A stronger business is not automatically the better stock. Starting valuation, expectations, capital structure, cyclicality, dilution, and the probability of each thesis determine the investment outcome. Use this comparison to frame the work, then verify the numbers in the linked filings and current company disclosures.
CVS Health Corporation and Danaher Corporation sit in the same Health Care sector but have different SEC industry classifications. The comparison is most useful for portfolio role and sector exposure, not as a claim that every product competes directly.
There is no context-free winner. Compare the operating exposures, filing evidence, valuation, balance sheet, and risks against the specific thesis you are testing. This page deliberately does not turn a static profile into a buy or sell recommendation.
No. Yield Theory does not republish unlicensed real-time market data. Use a regulated broker or licensed quote provider for current prices, then use the primary filings here to test the business thesis.
Company classifications, fiscal year-ends, and filing links come from the SEC EDGAR submissions API snapshot refreshed 2026-08-10. Business summaries and research themes are maintained by Yield Theory.
Data snapshot: SEC EDGAR submissions API, refreshed 2026-08-10. Independent educational research; not investment advice.
Yield Theory connects filings, capital flows, catalysts, and risks into an investable research process.
$15/mo or $150/yr · cancel future renewals anytime · sources included